Humanigen
Burlingame
About Humanigen
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $357.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2021)
- Ticker: otcqb:HGEN
- Website: humanigen.com
- Phone: 650-243-3100
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/humanigen-145222 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.